Last reviewed · How we verify

Albendazole plus Praziquantel — Competitive Intelligence Brief

Albendazole plus Praziquantel (Albendazole plus Praziquantel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihelmintic combination. Area: Infectious Disease / Parasitology.

marketed Antihelmintic combination β-tubulin (albendazole); calcium channels (praziquantel) Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

Albendazole plus Praziquantel (Albendazole plus Praziquantel) — Navrongo Health Research Centre, Ghana. Albendazole and praziquantel are antihelmintic agents that disrupt microtubule formation and parasite motility, causing paralysis and death of various parasitic worms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Albendazole plus Praziquantel TARGET Albendazole plus Praziquantel Navrongo Health Research Centre, Ghana marketed Antihelmintic combination β-tubulin (albendazole); calcium channels (praziquantel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihelmintic combination class)

  1. Navrongo Health Research Centre, Ghana · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Albendazole plus Praziquantel — Competitive Intelligence Brief. https://druglandscape.com/ci/albendazole-plus-praziquantel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: